Acadia Pharmaceuticals Inc. (ACAD) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 3.39B USD. 52-week range 19.32 to 30.96 USD. Trailing P/E 8.9. Data as of 2026-10-09.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett ...